This site is intended for healthcare professionals only

In association with the Cardiorenal Forum

Articles

  • Sodium–glucose cotransporter 2 inhibitors in heart failure: does it matter how they work?

  • EMPA-VISION: Cardiac energy in people with heart failure taking empagliflozin

  • Chronic kidney disease and incident heart failure: insights from the Atherosclerosis Risk in Communities study

  • Haemodialysis-related acute brain injury

  • Optimising heart failure treatment for patients on peritoneal dialysis

    Optimising heart failure treatment for patients on peritoneal dialysis

  • Sacubitril/valsartan in peritoneal dialysis patients

    Sacubitril/valsartan in peritoneal dialysis patients

  • RADIANCE II: endovascular ultrasound renal denervation as a treatment for hypertension

    RADIANCE II: endovascular ultrasound renal denervation as a treatment for hypertension

  • The safety of sodium–glucose cotransporter-2 inhibitors in people with chronic kidney disease and type 2 diabetes

    The safety of sodium–glucose cotransporter-2 inhibitors in people with chronic kidney disease and type 2 diabetes

  • MyTEMP trial: Is this the end of “cooled dialysis”?

alt

For the latest news and articles
Sign up to Renal Review newsletters

Subscribe